Nxera experiences constructive outcomes for the part III insomnia trial of daridorexant
Nxera Pharma has introduced constructive outcomes from its Section III trial of daridorexant 50 mg, geared toward treating insomnia in grownup and aged sufferers in South Korea.
The corporate plans to submit a advertising and marketing authorization software for this therapy within the first quarter of 2026, with approval anticipated within the first quarter of 2027.
Uncover B2B advertising and marketing that delivers
Mix enterprise intelligence and editorial excellence to achieve engaged professionals throughout 36 main media platforms.
Extra info
Daridorexant, accredited as Quviviq in Japan, is marketed by way of a partnership between Nxera and Shionogi.
Moreover, Idorsia Prescribed drugs markets the remedy in Canada, the US and a number of other European nations, whereas Simcere handles distribution in Hong Kong and China.
Insomnia impacts each bodily and psychological well being and impacts 15%-25% of the South Korean grownup inhabitants.
The part III, placebo-controlled, double-blind, randomized, multicenter examine is designed to evaluate the security and efficacy of daridorexant.
Contributors had been instructed to obtain daridorexant 50 mg or a placebo day by day for 28 days. The examine met each major and secondary efficacy endpoints.
The outcomes confirmed that daridorexant considerably improved subjective whole sleep time on day 28 in comparison with placebo.
Enhancements had been additionally noticed in secondary endpoints equivalent to subjective sleep onset awakening (sWASO) and subjective sleep onset latency (sLSO).
Adversarial occasions had been comparable between teams, with treatment-emergent adversarial occasions reported in 13.41% for the daridorexant group and 14.81% for placebo.
Nxera Pharma Korea President and Consultant Director MinBok Lee mentioned: “Insomnia is widespread in South Korea and represents a severe well being situation. We’re very inspired by the constructive outcomes of this Section III examine, which represents a essential milestone as we put together to submit a advertising and marketing authorization software within the first quarter of 2026.
“This development brings insomnia sufferers in South Korea one step nearer to having access to an necessary new therapy possibility. With Quviviq already out there within the US, Europe and Japan, we need to work to make this drugs out there to sufferers in South Korea as shortly as doable.”
